GLP-1 drugs and men's fat loss: separating hype from trial data

What did @susacharmd actually say?

In this clip, a physician is examining a male patient's midsection and telling him something specific about the nature of his belly fat. Her exact words: "This is a continuous fat. This is visceral fat that you can't pinch." The implication is that fat you cannot grab between your fingers is, by definition, visceral fat, and that this is meaningfully different from fat you can pinch. She connects this observation to a 12-pound figure, presumably weight already lost or a target. The claim is anatomical and clinical, so it deserves scrutiny rather than a pass just because a physician said it.

This is actually a teaching moment that shows up a lot in weight loss content. The idea sounds intuitive. If your belly feels firm and you can't grab it, it must be deep, dangerous fat around your organs. That logic is partly right and partly oversimplified in ways that matter for patients trying to understand their own bodies.

Does the science back this up?

Partially. Visceral fat is real, well-studied, and genuinely more metabolically dangerous than subcutaneous fat. But the claim that fat you cannot pinch equals visceral fat is an oversimplification that conflates two different phenomena. The pinch test is not a reliable clinical diagnostic for visceral versus subcutaneous fat.

Visceral adipose tissue (VAT) sits inside the abdominal cavity, surrounding organs like the liver, pancreas, and intestines. It is associated with insulin resistance, cardiovascular disease risk, and systemic inflammation. That part is well established (Fox et al., 2007, Circulation). However, subcutaneous fat, the kind sitting just under your skin, can also feel firm and be difficult to pinch depending on the person's muscle tone, skin laxity, and fat distribution pattern. A firm abdomen is not automatically visceral fat. Some people accumulate subcutaneous fat in a denser, more fibrous pattern that resists pinching entirely. Imaging studies, specifically MRI and CT scanning, remain the gold standard for distinguishing VAT from subcutaneous fat. The pinch test tells you nothing definitive about which compartment you're dealing with.

What did they get wrong (or right)?

Credit where it's due: the broader educational point, that visceral fat is a serious metabolic concern distinct from surface-level fat, is accurate and worth communicating. Men disproportionately accumulate visceral fat compared to premenopausal women, and that pattern carries real cardiovascular and metabolic risk (Jensen, 2008, New England Journal of Medicine). Raising awareness about that is genuinely useful.

What she got wrong is the diagnostic shortcut. Telling a patient, or 195,000 TikTok viewers, that fat you cannot pinch is visceral fat collapses a complex anatomical distinction into a bedside heuristic that does not hold up. Some visceral fat coexists with plenty of pinchable subcutaneous fat. Some people with significant subcutaneous fat in a dense distribution also have low visceral fat. You simply cannot tell from touch. This kind of shortcut can mislead patients into either overestimating or underestimating their metabolic risk based on how their belly feels. That has real consequences for whether someone seeks appropriate screening or assumes they're fine because their gut is soft.

What should you actually know?

The distinction between visceral and subcutaneous fat matters clinically, but the pinch test is not how you measure it. If you're concerned about visceral fat, the most practical proxy in a clinical setting is waist circumference. A waist circumference above 40 inches in men is associated with elevated cardiometabolic risk (National Institutes of Health guidelines). Waist-to-hip ratio is another accessible metric used in research settings.

For patients using GLP-1 receptor agonists like semaglutide or tirzepatide, the fat loss story is actually more nuanced and promising than the pinch test suggests. A 2023 trial by Wilding et al. in Nature Medicine found that tirzepatide preferentially reduced visceral fat relative to subcutaneous fat, which may explain some of its outsized metabolic benefits beyond the weight on the scale. That's a clinically meaningful finding that goes well beyond what you can assess by pressing on someone's stomach. If you're trying to understand your own fat distribution, talk to a clinician about waist circumference tracking or imaging if your risk profile warrants it, not the pinch test.